Hypertension as a Risk Factor for Atherosclerosis

Kirabo, Annet; Harrison, David G.

doi:10.1002/9781118828533.ch6

Cited by 2 publications

(2 citation statements)

References 76 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…Адипоциты и активированные макрофаги жировой ткани про-дуцируют большое количество цитокинов и вазоактивных веществ, которые вызывают воспаление и вазоконстрикцию, влияют на активность моноцитов и макрофагов, ведут к развитию лейкоцитоза [1]. А АГ посредством различных молекулярных и гемодинамических факторов способствует формированию благоприятного фона для формирования АСБ [18]. Кроме того, предполагается, что АГ может выступать непосредственным фактором их дестабилизации наряду с воспалением [19].…”

Section: патофизиологические механизмы развития ссз у пациентов с пре...unclassified

Prediabetes: a risk factor for cardiovascular diseases and a window of opportunity for their prevention

Demidova

Plakhotnyaya²

2023

jour

View full text Add to dashboard Cite

It’s well known, that diabetes mellitus predisposes to more rapid development and progression of cardiovascular disease (CVD) and cardiomyopathy. However, the pathological changes underlying them begin to form much earlier — at the stage of prediabetes. Individuals with prediabetes have a higher risk of atherosclerosis and chronic heart failure, as well as increased rates of mortality from CVD and all-cause death. This review is devoted to the analysis of pathophysiological mechanisms that lead to developing CVD in patients with early prediabetes. In addition, the article highlights the issues of preventing the development of cardiovascular pathology in this group of patients with an emphasis on the active impact on the main factors of cardiovascular risk.

show abstract

Section: патофизиологические механизмы развития ссз у пациентов с пре...unclassified

Prediabetes: a risk factor for cardiovascular diseases and a window of opportunity for their prevention

Demidova

Plakhotnyaya²

2023

jour

View full text Add to dashboard Cite

show abstract

“…The deleterious effects of arterial hypertension are due to multiple mechanisms, including endothelial dysfunction induced by mechanical and hemodynamic stress, increase of atherogenic lipoprotein uptake into the intima and monocyte adherence to the endothelial line. Further, vascular inflammation, promotion of the synthetic state of VSMCs and the activation of prothrombotic factors via angiotensin (Ang) II and other vasoconstrictive peptides play significant roles [41][42][43]. In addition to its established role in hypertension, the renin-angiotensin system (RAS) has major implications in atherosclerosis pathogenesis via various cellular and molecular mechanisms.…”

Section: Classical Risk Factors Hypercholesterolemiamentioning

confidence: 99%

Therapeutic Strategies and Chemoprevention of Atherosclerosis: What Do We Know and Where Do We Go?

Aprotosoaie

Costache

2022

Pharmaceutics

View full text Add to dashboard Cite

Despite progress in understanding the pathogenesis of atherosclerosis, the development of effective therapeutic strategies is a challenging task that requires more research to attain its full potential. This review discusses current pharmacotherapy in atherosclerosis and explores the potential of some important emerging therapies (antibody-based therapeutics, cytokine-targeting therapy, antisense oligonucleotides, photodynamic therapy and theranostics) in terms of clinical translation. A chemopreventive approach based on modern research of plant-derived products is also presented. Future perspectives on preventive and therapeutic management of atherosclerosis and the design of tailored treatments are outlined.

show abstract

Hypertension as a Risk Factor for Atherosclerosis

Cited by 2 publications

References 76 publications

Prediabetes: a risk factor for cardiovascular diseases and a window of opportunity for their prevention

Prediabetes: a risk factor for cardiovascular diseases and a window of opportunity for their prevention

Therapeutic Strategies and Chemoprevention of Atherosclerosis: What Do We Know and Where Do We Go?

Contact Info

Product

Resources

About